Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Sudden Cardiac Death: Pharmacotherapy and Proarrhythmic Drugs: A Nationwide Cohort Study in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact of Physician-staffed Helicopters on Pre-hospital Patient Outcomes: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Sudden Cardiac Death in the Young

    Research output: Contribution to journalReviewResearchpeer-review

  3. Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With ST-Segment-Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Genome-wide association study identifies locus at chromosome 2q32.1 associated with syncope and collapse

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Seasonality of ventricular fibrillation at first myocardial infarction and association with viral exposure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: This study sought to describe the use of pharmacotherapy in a nationwide cohort of young patients with sudden cardiac death (SCD).

BACKGROUND: Several drugs have been associated with an increased risk of SCD and sudden arrhythmic death syndrome (SADS). It remains unclear how pharmacotherapy may contribute to the overall burden of SCD in the general population.

METHODS: This was a nationwide study that included all deaths that occurred between 2000 and 2009 and between 2007 and 2009 in people age 1 to 35 years and 36 to 49 years, respectively. Two physicians identified all SCDs through review of death certificates. Autopsy reports were collected. Pharmacotherapy prescribed within 90 days before SCD was identified in the Danish Registry of Medicinal Product Statistics.

RESULTS: We identified 1,363 SCDs; median age was 38 years (interquartile range: 29 to 45 years), and 72% (n = 975) were men. Autopsy was performed in 55%. Overall, 58% of SCD cases (n = 786) received at least 1 drug within 90 days before death. The most common drugs were analgesic drugs (n = 239; 18%), antihypertensive drugs (n = 234; 17%), and antibiotic drugs (n = 218; 16%). After multivariable adjustment, prescription of "brugadogenic" drugs or >1 QT-prolonging drug was associated with an increased risk of SADS compared with explained SCD (odds ratio: 2.16 [95% confidence interval: 1.12 to 4.17] and 2.91 [95% confidence interval: 1.46 to 5.81], respectively).

CONCLUSIONS: Pharmacotherapy was identified in 58% of the SCD cases. After multivariable adjustment, there was a 2- and 3-fold increased risk of SADS compared with explained SCD in patients receiving brugadogenic drugs or >1 QT-prolonging drug, respectively. Identification of high-risk patients is warranted to lower the burden of SCD.

Original languageEnglish
JournalJACC. Clinical electrophysiology
Volume3
Issue number5
Pages (from-to)473-481
Number of pages9
ISSN2405-500X
DOIs
Publication statusPublished - May 2017

ID: 56381286